CommercialPrior AuthMedium impact
Idursulfase (Elaprase®)
BCBS Tennessee·TN · Genetics, Pediatrics, Internal Medicine·Medical Policy
Effective date
Sep 30, 2026
We identified it
Jul 17, 2026
Summary
BlueCross BlueShield of Tennessee has issued a new medical policy for Idursulfase (Elaprase®) for treatment of Hunter syndrome (Mucopolysaccharidosis II, MPS II) effective 9/30/2026. The policy establishes coverage criteria requiring confirmed enzyme deficiency diagnosis, clinical disease symptoms at baseline, specialist prescription, and documented clinical response for continuation therapy. Prior authorization is required with specific documentation including diagnostic confirmation and disease progression monitoring.
Action Required
By September 30, 2026: Billing team must implement prior authorization requirements for Idursulfase (Elaprase®) claims in BCBS Tennessee plans. Update billing system to: (1) require prior authorization submission for all new Idursulfase requests with documented iduronate-2-sulfatase enzyme assay/genetic testing results and baseline clinical disease documentation; (2) flag continuation requests (reauthorization) requiring evidence of clinical response (improvement, stabilization, or slowing of disease progression); (3) verify treating physician is a metabolic disease or lysosomal storage disorder specialist before processing. Billing team must add to prior authorization checklist: diagnosis confirmation documentation, baseline clinical signs/symptoms, and for continuations, specific disease progression markers (FVC, 6-minute walk test, joint range of motion, organ volume, or urine glycosaminoglycan levels). Front desk/authorization staff should reject incomplete submissions. Failure to obtain proper prior authorization will result in claim denials. Note: Policy states 'Do Not Implement until 9/30/26'—do NOT implement before this date.